Molly S. Griffith

485 total citations
16 papers, 375 citations indexed

About

Molly S. Griffith is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Social Psychology. According to data from OpenAlex, Molly S. Griffith has authored 16 papers receiving a total of 375 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Cellular and Molecular Neuroscience and 5 papers in Social Psychology. Recurrent topics in Molly S. Griffith's work include Neuroendocrine regulation and behavior (5 papers), Receptor Mechanisms and Signaling (4 papers) and Neuroscience and Neuropharmacology Research (3 papers). Molly S. Griffith is often cited by papers focused on Neuroendocrine regulation and behavior (5 papers), Receptor Mechanisms and Signaling (4 papers) and Neuroscience and Neuropharmacology Research (3 papers). Molly S. Griffith collaborates with scholars based in United States and United Kingdom. Molly S. Griffith's co-authors include Mark E. Bardgett, Patrick J. Schultheis, Marc E. Rothenberg, Ting Wen, Brad T. Tinkle, Margaret H. Collins, Lisa J. Martin, James P. Franciosi, Stephanie M. Ware and Emily M. Stucke and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Allergy and Clinical Immunology and Neuropsychopharmacology.

In The Last Decade

Molly S. Griffith

15 papers receiving 368 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Molly S. Griffith United States 10 120 112 102 97 66 16 375
Kaku Niimura Japan 8 24 0.2× 158 1.4× 12 0.1× 82 0.8× 64 1.0× 17 378
Tatiana Brémovà-Ertl Germany 16 20 0.2× 21 0.2× 47 0.5× 199 2.1× 145 2.2× 37 764
Anna Laura Abbamondi Italy 9 32 0.3× 57 0.5× 26 0.3× 160 1.6× 169 2.6× 10 407
Ronnie Gorman Swift United States 7 113 0.9× 17 0.2× 9 0.1× 395 4.1× 41 0.6× 17 702
Irina N. Bespalova United States 13 33 0.3× 11 0.1× 40 0.4× 285 2.9× 74 1.1× 20 646
Ludovic J. Wrobel Switzerland 12 22 0.2× 94 0.8× 7 0.1× 105 1.1× 95 1.4× 17 450
F. Pousset France 10 10 0.1× 145 1.3× 10 0.1× 78 0.8× 55 0.8× 13 445
Kitty Reemst Netherlands 8 19 0.2× 87 0.8× 4 0.0× 112 1.2× 80 1.2× 9 537
A. Rosina Italy 14 21 0.2× 52 0.5× 6 0.1× 74 0.8× 215 3.3× 20 504
Zhen-Yu Wu China 7 11 0.1× 9 0.1× 32 0.3× 72 0.7× 90 1.4× 18 339

Countries citing papers authored by Molly S. Griffith

Since Specialization
Citations

This map shows the geographic impact of Molly S. Griffith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Molly S. Griffith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Molly S. Griffith more than expected).

Fields of papers citing papers by Molly S. Griffith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Molly S. Griffith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Molly S. Griffith. The network helps show where Molly S. Griffith may publish in the future.

Co-authorship network of co-authors of Molly S. Griffith

This figure shows the co-authorship network connecting the top 25 collaborators of Molly S. Griffith. A scholar is included among the top collaborators of Molly S. Griffith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Molly S. Griffith. Molly S. Griffith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Bardgett, Mark E., et al.. (2024). Early-life risperidone alters locomotor responses to apomorphine and quinpirole in adulthood. Behavioural Brain Research. 473. 115171–115171. 1 indexed citations
2.
Capal, Jamie K., David M. Ritter, David Neal Franz, et al.. (2024). Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy results. SHILAP Revista de lepidopterología. 2(2). 106–119. 7 indexed citations
3.
Harrison, Judith R., et al.. (2022). Comparison of Four Classroom-Based Strategies for Middle School Students With ADHD: A Pilot Randomized Controlled Trial. Journal of Attention Disorders. 26(11). 1507–1519. 6 indexed citations
4.
Capal, Jamie K., Paul S. Horn, Molly S. Griffith, et al.. (2021). Epilepsy Is Heterogeneous in Early-Life Tuberous Sclerosis Complex. Pediatric Neurology. 123. 1–9. 13 indexed citations
5.
Gosnell, Elizabeth S., et al.. (2021). Oral Manifestations and Quality of Life in Children with Tuberous Sclerosis Complex: A Descriptive Study.. PubMed. 43(2). 140–144.
6.
Fidelman, Nicholas, Chloé E. Atreya, Molly S. Griffith, et al.. (2020). 3:54 PM Abstract No. 243 Phase I Prospective Trial of TAS-102 (trifluride and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases. Journal of Vascular and Interventional Radiology. 31(3). S109–S109. 1 indexed citations
7.
Griffith, Molly S., et al.. (2016). Delayed yet persistent effects of daily risperidone on activity in developing rats. Behavioural Pharmacology. 27(5). 460–469. 8 indexed citations
8.
Griffith, Molly S., et al.. (2015). Early-life risperidone administration alters maternal–offspring interactions and juvenile play fighting. Pharmacology Biochemistry and Behavior. 130. 90–96. 12 indexed citations
9.
Bardgett, Mark E., et al.. (2014). Comparison of Neurological Function in Males and Females from Two Substrains of C57BL/6 Mice. Toxics. 3(1). 1–17. 17 indexed citations
10.
Bardgett, Mark E., et al.. (2013). Adult rats treated with risperidone during development are hyperactive.. Experimental and Clinical Psychopharmacology. 21(3). 259–267. 23 indexed citations
11.
Abonia, J. Pablo, Ting Wen, Emily M. Stucke, et al.. (2013). High prevalence of eosinophilic esophagitis in patients with inherited connective tissue disorders. Journal of Allergy and Clinical Immunology. 132(2). 378–386. 138 indexed citations
12.
Bardgett, Mark E., et al.. (2010). Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APPTg2576 mouse model of Alzheimer’s disease. Neurobiology of Learning and Memory. 95(1). 64–72. 61 indexed citations
13.
Bardgett, Mark E., et al.. (2010). The H3 antagonist, ciproxifan, alleviates the memory impairment but enhances the motor effects of MK-801 (dizocilpine) in rats. Neuropharmacology. 59(6). 492–502. 25 indexed citations
14.
Bardgett, Mark E., et al.. (2009). Effects of the H3 antagonist, thioperamide, on behavioral alterations induced by systemic MK-801 administration in rats. Psychopharmacology. 205(4). 589–597. 23 indexed citations
15.
Bardgett, Mark E., et al.. (2007). The Effects of Clonidine on Discrete-Trial Delayed Spatial Alternation in Two Rat Models of Memory Loss. Neuropsychopharmacology. 33(8). 1980–1991. 20 indexed citations
16.
Bardgett, Mark E., et al.. (2005). The effects of clozapine on delayed spatial alternation deficits in rats with hippocampal damage. Neurobiology of Learning and Memory. 85(1). 86–94. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026